Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-08-20

FDA Approved: LAMIVUDINE — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

FDA approved a supplemental application to authorize lamivudine oral (generic) from Chartwell RX, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lamivudine (lamivudine)

Snippet

SUPPL AP for LAMIVUDINE (LAMIVUDINE ORAL)